It’s an important nod for Novartis, which has bet big on the radiopharmaceutical industry. The approval nearly doubles the eligible patient population for Pluvicto.
The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients.
The approval nearly doubles the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling eligible patients.
The FDA has expanded approval for a radioligand therapy that nearly doubles the number of men with advanced prostate cancer…
Novartis's Pluvicto was approved by the Food and Drug Administration for use in combination with an androgen receptor pathway…
Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This…
Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales,…
Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision oncology…
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)
FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31
Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
